Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticlePDA Papers

Demonstrating Pharmaceutical Quality System Effectiveness and Driving Continual Improvement: Evidence-Based Risk Reduction

Emma Ramnarine and Kevin O'Donnell
PDA Journal of Pharmaceutical Science and Technology May 2018, 72 (3) 338-345; DOI: https://doi.org/10.5731/pdajpst.2017.008524
Emma Ramnarine
Sr. Director, Head Global Analytical Science and Technology, Genentech/Roche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: eramnar@gene.com
Kevin O'Donnell
Market Compliance Manager, Health Products Regulatory Authority (HPRA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Reference

  1. 1.↵
    Quality Guideline Q10: Pharmaceutical Quality System. ICH, 2010. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html (accessed October 2017).
  2. 2.↵
    Quality Guideline Q8(R2): Pharmaceutical Development. ICH, 2009. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf (accessed October 2017).
  3. 3.↵
    Quality Guideline Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). ICH, 2012. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html (accessed October 2017).
  4. 4.↵
    Eudralex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Chapter 1. Pharmaceutical Quality System. September 2012. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/vol4-chap1_2013-01_en.pdf (accessed October 2017).
  5. 5.↵
    Guidance for Industry PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. September 2004. https://www.fda.gov/downloads/drugs/guidances/ucm070305.pdf (accessed October 2017).
  6. 6.↵
    ICH Q12 Final Concept Paper: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Endorsed by ICH Steering Committee 9 September 2014. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Concept_Paper_July_2014.pdf (accessed November 2017).
  7. 7.↵
    See HPRA Annual Reports 2005–2016. Available at www.hpra.ie.
  8. 8.↵
    1. O'Donnell K.
    , QRM in the GMP Environment: Ten Years On … Are Medicines Any Safer Now? A Regulator's Perspective. J. Valid. Technol. 2015, 21 (4), 9.
    OpenUrl
  9. 9.↵
    1. Ramnarine E.,
    2. Busse U.,
    3. Chassant F.,
    4. Edwards J.,
    5. O'Donnell K.,
    6. Jornitz M.,
    7. Munk M.,
    8. Seymour M.,
    9. Simianu M.,
    10. Skeens L.,
    11. Vinther A.
    PDA Points to Consider: Technical Product Lifecycle Management Pharmaceutical Quality System Effectiveness for Managing Post-Approval Changes. PDA J. Pharm. Sci. Technol. 2017, 71 (3), 252–258.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Morgan M. G.,
    2. Henrion M.
    Uncertainty—A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis; Cambridge University Press: New York, 1990.
  11. 11.↵
    1. Morgan M. G.,
    2. Morris S. C.,
    3. Henrion M.,
    4. Amaral D. A. L.,
    5. Rish W. R.
    ; Technical Uncertainty in Quantitative Policy Analysis: A Sulphur Air Pollution Example. Risk Analysis 1984, 4 (3), 201–216.
    OpenUrlCrossRefWeb of Science
  12. 12.↵
    1. Mullen T. M.
    Understanding and Supporting the Process of Probabilistic Estimation, PhD Dissertation, Carnegie Mellon University, Pittsburgh, 1986.
  13. 13.↵
    1. Rasmussen N. C.
    The Application of Probabilistic Risk Assessment Techniques to Energy Technologies. Ann. Rev. Energy 1981, 6 (1), 123–138.
    OpenUrlCrossRef
  14. 14.↵
    1. Stamatelatos M.
    Probabilistic Risk Assessment—What Is It and Why Is It Worth Performing? NASA Office of Safety and Mission Assurance, May 4, 2000, available from www.hq.nasa.gov (accessed November 28, /2007).
  15. 15.↵
    1. Greenfield M. A.
    The Inherent Values of Probabilistic Risk Assessment (Presentation), June 19, 2001, NASA Office of Safety and Mission Assurance, available from http://www.hq.nasa.gov/office/codeq/risk/risk_archive.htm (accessed November 29, /2007).
  16. 16.↵
    1. Kaplan S.,
    2. Garrick B. J.
    “On the Quantitative Definition of Risk.” Risk Analysis 1981, 1 (1), 11–27.
    OpenUrlCrossRef
  17. 17.↵
    1. Kmenta S.,
    2. Ishii K.
    Scenario-Based Failure Modes and Effects Analysis Using Expected Cost. Journal of Mechanical Design 2004, 126 (6), 1027–1035.
    OpenUrl
  18. 18.↵
    1. Schmidt M. W.
    The Use and Misuse of FMEA in Risk Analysis. Medical Device & Diagnostic Industry 2004, 26, 56–61.
    OpenUrl
  19. 19.↵
    1. Rhee J.,
    2. Ishii K.
    Using Cost Based FMEA To Enhance Reliability and Serviceability. Advanced Engineering Informatics 2003, 17 (3-4), 179–188.
    OpenUrlCrossRef
  20. 20.↵
    1. Bowles J. B.
    An Assessment of RPN Prioritization in a Failure Modes Affects and Criticality Analysis. Reliability and Maintainability Symposium 2003, 380–386; available at http://ieeexplore.ieee.org (posted online: 2003-02-28).
  21. 21.↵
    1. O'Donnell K.,
    2. Zwitkovits M.,
    3. Greene A.,
    4. Calnan N.
    Quality Risk Management—Putting GMP Controls First. PDA J. Pharm. Sci. Technol. 2012, 66 (3), 243–261.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Kahneman D.,
    2. Tversky A.
    Subjective Probability: A Judgement of Representativeness. Cognitive Psychology 1972, 3, 430–354.
    OpenUrlCrossRefWeb of Science
  23. 23.↵
    1. Kahneman D,
    2. Slovic P,
    3. Tversky A
    1. Lichtenstein S.,
    2. Fischhoff B.,
    3. Phillips L. D.
    Calibration of Probabilities: The State of the Art to 1980. In Judgement under Uncertainty: Heuristics and Biases, Kahneman D, Slovic P, Tversky A, Eds.; Cambridge University Press: New York, 1982.
  24. 24.↵
    1. Keller A. Z.
    Perception and Quantification of Risk. ISPRA courses, Reliability and Data, JRC ISPRA, 21020, Italy, 1984.
  25. 25.↵
    1. Fischhoff B.,
    2. Slovic P.,
    3. Lichtenstein S.
    Fault Trees: Sensitivity of Estimated Failure Probabilities to Problem Representation. J. Exp. Psychol.—Human Perception Perf. 1978, 4, 330–444.
    OpenUrl
  26. 26.↵
    1. Kahneman D.,
    2. Tversky A.
    “On the Psychology of Prediction.” Psychological Review 1973, 80 (4), 237–251.
    OpenUrlCrossRefWeb of Science
  27. 27.↵
    1. Goldberg L. R.
    The Effectiveness of Clinicians' Judgements: The Diagnosis of Organic Brain Damage from the Bender-Gestalt Test. Journal of Consulting Psychologists 1959, 23, 23–33.
    OpenUrl
  28. 28.↵
    1. Wallsten T. S.,
    2. Budescu D. V.,
    3. Rapoport A.,
    4. Zwick R.,
    5. Forsyth B.
    Measuring the Vague Meaning of Probability Terms. Journal of Experimental Psychology: General 1985, 115, 348–365.
    OpenUrl
  29. 29.↵
    1. Brier G. W.
    Verification of Forecasts Expressed in Terms of Probability. Monthly Weather Review 1950, 78, 1–3.
    OpenUrlCrossRef
  30. 30.↵
    1. Faust D.
    Declarations versus Investigations: The Case for the Special Reasoning Abilities and Capabilities of the Expert Witness in Psychology/Psychiatry. Journal of Psychiatry & Law 1985, 13 (1–2), 33–59.
    OpenUrl
  31. 31.↵
    1. Hoch S. J.
    Availability and Interference in Predictive Judgement. Journal of Experimental Psychology: Learning, Memory and Cognition 1984, 10 (4), 649.
    OpenUrlCrossRefWeb of Science
  32. 32.↵
    U.S. Nuclear Regulatory Commission. An Approach for Using Probabilistic Risk Assessment in Risk-Informed Decisions on Plant-Specific Changes to the Licensing Basis, NRC Regulatory Guide No. 1.174, Revision 1, November 2002.
  33. 33.↵
    1. Hickman J. W.,
    2. et al
    ., PRA Procedures Guide – A Guide to the Performance of Probabilistic Risk Assessments for Nuclear Power Plants. American Nuclear Society, NUREG/CR-2300, Vols. 1 and 2, January 1983.
  34. 34.↵
    American Society of Mechanical Engineers. Standard for Probabilistic Risk Assessment for Nuclear Power Plant Applications, ASME RA-S-2002, April 2002.
  35. 35.↵
    1. MacDonald J. A.,
    2. Small M. J.,
    3. Morgan M. J.
    Explosion Probability of Unexploded Ordnance. Risk Analysis 2008, 28 (4), 825–841.
    OpenUrlPubMed
  36. 36.↵
    1. Coburn J.,
    2. Weddle G.
    Risk-Based Regulation, Learning from the Experience of Others. BioProcess International 2006, September, 22–28.
  37. 37.↵
    1. Coburn J.,
    2. Levinson S. H.,
    3. Weddle G.
    A Precedent for Risk-Based Regulation. Pharmaceutical Engineering 2005, July/August, 40–90.
  38. 38.↵
    1. Kunreuther H.,
    2. Novemsky N.,
    3. Kahneman K.
    Making Low Probabilities Useful. Journal of Risk and Uncertainty 2001, 23 (2), 103–120.
    OpenUrlCrossRefWeb of Science
  39. 39.↵
    1. O'Keeffe D.,
    2. Campbell C.,
    3. O'Donnell K.
    A Spectrum of Importance—Challenging the Concept of ‘Critical/Non-critical’ in Qualification and Validation Activities. J. Valid. Technol. 2016, 22 (1).
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 72 (3)
PDA Journal of Pharmaceutical Science and Technology
Vol. 72, Issue 3
May/June 2018
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Demonstrating Pharmaceutical Quality System Effectiveness and Driving Continual Improvement: Evidence-Based Risk Reduction
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Demonstrating Pharmaceutical Quality System Effectiveness and Driving Continual Improvement: Evidence-Based Risk Reduction
Emma Ramnarine, Kevin O'Donnell
PDA Journal of Pharmaceutical Science and Technology May 2018, 72 (3) 338-345; DOI: 10.5731/pdajpst.2017.008524

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Demonstrating Pharmaceutical Quality System Effectiveness and Driving Continual Improvement: Evidence-Based Risk Reduction
Emma Ramnarine, Kevin O'Donnell
PDA Journal of Pharmaceutical Science and Technology May 2018, 72 (3) 338-345; DOI: 10.5731/pdajpst.2017.008524
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Practical Implications
    • Risk Management and Knowledge Management
    • Role of the Pharmaceutical Quality System (PQS)
    • Estimation of Risk Reduction
    • Change Management and Risk Reduction
    • Enabling Regulatory Flexibility through an Effective PQS
    • Risk Management Learnings from Other Industries
    • Conflict of Interest Statement
    • Reference
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Achieving “Zero” Defects for Visible Particles in Injectables
  • PDA Points to Consider: Best Practices for Document/Data Management and Control and Preparing for Data Integrity Inspections
Show more PDA Papers

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2023 PDA Journal of Pharmaceutical Science and Technology ISSN: 1079-7440

Powered by HighWire